[go: up one dir, main page]

NO993901L - Bicyclic amino acids - Google Patents

Bicyclic amino acids

Info

Publication number
NO993901L
NO993901L NO993901A NO993901A NO993901L NO 993901 L NO993901 L NO 993901L NO 993901 A NO993901 A NO 993901A NO 993901 A NO993901 A NO 993901A NO 993901 L NO993901 L NO 993901L
Authority
NO
Norway
Prior art keywords
amino acids
bicyclic amino
bicyclic
acids
amino
Prior art date
Application number
NO993901A
Other languages
Norwegian (no)
Other versions
NO313289B1 (en
NO993901D0 (en
Inventor
Beate Diefenbach
Simon Goodman
Joachim Morz
Peter Raddatz
Friedrich Rippmann
Matthias Wiesner
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO993901D0 publication Critical patent/NO993901D0/en
Publication of NO993901L publication Critical patent/NO993901L/en
Publication of NO313289B1 publication Critical patent/NO313289B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/341,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/361,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D319/00Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/101,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/141,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/161,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/201,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO19993901A 1997-02-13 1999-08-12 Bisyclic amino acids, process for their preparation, pharmaceutical composition, process for their preparation, use of the compounds for the preparation of a drug use as <alfa> v-integrin inhibitor NO313289B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19705450A DE19705450A1 (en) 1997-02-13 1997-02-13 Bicyclic aromatic amino acids
PCT/EP1998/000636 WO1998035949A1 (en) 1997-02-13 1998-02-06 Bicyclic amino acids

Publications (3)

Publication Number Publication Date
NO993901D0 NO993901D0 (en) 1999-08-12
NO993901L true NO993901L (en) 1999-10-12
NO313289B1 NO313289B1 (en) 2002-09-09

Family

ID=7820093

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19993901A NO313289B1 (en) 1997-02-13 1999-08-12 Bisyclic amino acids, process for their preparation, pharmaceutical composition, process for their preparation, use of the compounds for the preparation of a drug use as <alfa> v-integrin inhibitor

Country Status (25)

Country Link
EP (1) EP0964856B1 (en)
JP (1) JP4327257B2 (en)
KR (1) KR20000071030A (en)
CN (1) CN1085205C (en)
AR (1) AR010894A1 (en)
AT (1) ATE225776T1 (en)
AU (1) AU735313B2 (en)
BR (1) BR9807345A (en)
CA (1) CA2280727C (en)
CY (1) CY2341B1 (en)
CZ (1) CZ297366B6 (en)
DE (2) DE19705450A1 (en)
DK (1) DK0964856T3 (en)
ES (1) ES2183332T3 (en)
HU (1) HUP0001138A3 (en)
ID (1) ID22533A (en)
NO (1) NO313289B1 (en)
PL (1) PL335101A1 (en)
PT (1) PT964856E (en)
RU (1) RU2187506C2 (en)
SI (1) SI0964856T1 (en)
SK (1) SK284646B6 (en)
TR (1) TR199901962T2 (en)
WO (1) WO1998035949A1 (en)
ZA (1) ZA981178B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063790A1 (en) * 1996-05-31 2004-04-01 The Scripps Research Institute Methods for inhibition of angiogenesis
JP4064059B2 (en) 1998-04-09 2008-03-19 明治製菓株式会社 Aminopiperidine derivatives as integrin αVβ3 antagonists
JP3936844B2 (en) 1999-04-13 2007-06-27 ビーエーエスエフ アクチェンゲゼルシャフト Integrin receptor ligand
AU6316900A (en) 1999-08-05 2001-03-05 Meiji Seika Kaisha Ltd. Omega-amino-alpha-hydroxycarboxylic acid derivatives having integrin alphavbeta3antagonism
WO2001047874A1 (en) * 1999-12-24 2001-07-05 Smithkline Beecham P.L.C. (hetero)bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives
EP1170287B1 (en) * 2000-01-25 2003-12-03 Kaneka Corporation Process for preparation of optically active n-substituted azetidine-2-carboxylic acids
ATE415163T1 (en) * 2000-11-01 2008-12-15 Merck Patent Gmbh METHODS AND COMPOSITIONS FOR TREATING EYE DISEASES
EP1404860B8 (en) 2001-05-30 2013-12-25 The Scripps Research Institute Delivery system for nucleic acids
KR20040028966A (en) 2001-08-01 2004-04-03 메르크 파텐트 게엠베하 Integrin inhibitors for the treatment of eye diseases
MXPA04007770A (en) * 2002-02-14 2004-10-15 Merck Patent Gmbh Methods and compositions for the treatment of eye diseases.
DE10305784A1 (en) * 2003-02-12 2004-08-26 Merck Patent Gmbh 3-Oxo-3,4-dihydro-2H-benz-(1,4)-oxazin-6-yl)-propionic acid derivative preparation, for use as integrin inhibitors with e.g. antitumor action, by multi-stage process giving diastereomerically pure product
DE10337863A1 (en) 2003-08-18 2005-03-17 Merck Patent Gmbh Use of chromene-4-one derivatives
EP2484365B1 (en) * 2004-06-04 2013-10-02 The Scripps Research Institute Compositions and method for treatment of neovascular diseases
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
PL2380881T3 (en) * 2008-12-26 2017-07-31 Sumitomo Dainippon Pharma Co., Ltd. Novel bicyclic heterocyclic compound
WO2011024987A1 (en) * 2009-08-31 2011-03-03 塩野義製薬株式会社 Aromatic fused heterocyclic derivative and pharmaceutical composition containing same
MX2014010563A (en) 2012-03-06 2014-12-05 Boehringer Ingelheim Int Benzodioxanes in combination with other actives for inhibiting leukotriene production.
WO2014014874A1 (en) 2012-07-17 2014-01-23 Boehringer Ingelheim International Gmbh Pyrazole derivatives which inhibit leukotriene production
US9303018B2 (en) 2013-07-15 2016-04-05 Boehringer Ingelheim International Gmbh Inhibitors of leukotriene production
JP2016523982A (en) 2013-07-15 2016-08-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Inhibitors of leukotriene production
US10328082B2 (en) 2014-05-30 2019-06-25 Pfizer Inc. Methods of use and combinations
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators
CA3221177A1 (en) 2021-11-01 2023-05-04 Meghan Kerrisk Campbell Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU675689B2 (en) * 1992-12-01 1997-02-13 Merck & Co., Inc. Fibrinogen receptor antagonists
JPH10501222A (en) * 1994-05-27 1998-02-03 メルク エンド カンパニー インコーポレーテッド Compounds for inhibiting osteoclast-mediated bone resorption
DE19548709A1 (en) * 1995-12-23 1997-07-03 Merck Patent Gmbh Tyrosine derivatives
EP0907637A1 (en) * 1996-06-28 1999-04-14 MERCK PATENT GmbH Phenylalamine derivatives as integrin inhibitors
DE19654483A1 (en) * 1996-06-28 1998-01-02 Merck Patent Gmbh Phenylalanine derivatives

Also Published As

Publication number Publication date
AU735313B2 (en) 2001-07-05
SK107199A3 (en) 2000-05-16
EP0964856B1 (en) 2002-10-09
PL335101A1 (en) 2000-04-10
ZA981178B (en) 1999-05-21
CZ287599A3 (en) 1999-11-17
DE59805895D1 (en) 2002-11-14
RU2187506C2 (en) 2002-08-20
BR9807345A (en) 2000-03-21
HUP0001138A3 (en) 2002-10-28
NO313289B1 (en) 2002-09-09
JP2001511789A (en) 2001-08-14
KR20000071030A (en) 2000-11-25
NO993901D0 (en) 1999-08-12
ATE225776T1 (en) 2002-10-15
JP4327257B2 (en) 2009-09-09
SI0964856T1 (en) 2003-04-30
CN1252064A (en) 2000-05-03
ES2183332T3 (en) 2003-03-16
PT964856E (en) 2003-02-28
HUP0001138A2 (en) 2001-05-28
DK0964856T3 (en) 2003-02-10
CA2280727C (en) 2008-05-06
EP0964856A1 (en) 1999-12-22
CZ297366B6 (en) 2006-11-15
TR199901962T2 (en) 1999-12-21
CY2341B1 (en) 2004-02-06
CN1085205C (en) 2002-05-22
SK284646B6 (en) 2005-08-04
CA2280727A1 (en) 1998-08-20
WO1998035949A1 (en) 1998-08-20
ID22533A (en) 1999-10-28
AU6620698A (en) 1998-09-08
AR010894A1 (en) 2000-07-12
DE19705450A1 (en) 1998-08-20

Similar Documents

Publication Publication Date Title
NO993901L (en) Bicyclic amino acids
ATE238984T1 (en) SULFONYLAMINOCARBOXYLIC ACIDS
NO20002990L (en) New surface protein
DE69839603D1 (en) ORNAMENTAL PROTEINS
FI953837A0 (en) Synthetic activating amino acids
IS5375A (en) KAY-Innovative Immune Protein
NO2010013I1 (en) Recombinant FSH-CTP
DE69832623D1 (en) MICRO-MADE CIRCLES
NO985680D0 (en) peptide
NO994548D0 (en) Railing
DE69815952D1 (en) polisher
NO983849L (en) peptide
DE69816146D1 (en) polisher
DE69830139D1 (en) ULTRASONIC LOCKENWICKELGERÄT
BR9609671A (en) Amino uracilas substituted
DE69838161D1 (en) polisher
TR199701666A3 (en) Proteins
DE69808762D1 (en) CONNECTION PART
DE69834398D1 (en) PENDANT
DE59806788D1 (en) Lights Set
DK1017798T3 (en) lunasin peptides
NO20000976D0 (en) peptides
ATA188297A (en) FITTING
ATE204219T1 (en) BOND HEAD
ITMI972543A0 (en) P27BBP PROTEIN

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees